Apalutamide Submitted to FDA for Treatment of Metastatic Castration-Sensitive Prostate Cancer

[Longterm101]

targetedonc.com/news/apalut...

[cesanon]

Looks like it's just for bone metastasies

"Patients with small cell, ductal, or neuroendocrine carcinoma of the prostate, brain metastases, lymphatic metastases, visceral metastases, a prior malignancy within 5 years of randomization, a history of seizures, or prior treatment with other next-generation AR inhibitors or CYP17 inhibitors, immunotherapy, or radiopharmaceutical agents were excluded. "

[6357axbz]

Do these results make this the best treatment for mCSPCa? Better than Abiraterone?

[6357axbz]

I’m surprised your post didn’t receive more replies. This could be huge for those of us mCSPCa, better than Zytiga.

[Longterm101 in reply to 6357axbz]

Let’s hope and pray for this and more to come

[snoraste]

Thanks for the post. Looks like Darolutamide is getting priority review by FDA as well for nm-CRPS as well. Performance seems very similar to Elreada. So hopefully that will also be fast-tracked for mCPRC and mHSPC in a year or tow as well.

[monte1111]

Sounds like most of us are excluded. Don't you just hate that. Those were test exclusions, to make their product look better I am guessing. Maybe they will open it up a little to a wider pool. Hang on to your wallets.